This is a ready-to-use protocol for a forced degradation, or stress, study: the controlled overstress of a candidate formulation to generate known degradation products, so an analytical method can be proven stability-indicating before it is trusted to support a real stability program. Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through your normal document control, review, and approval before execution. A filled specimen follows. Verify each cited reference against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | Forced Degradation Study Protocol for <<FILL: product / candidate formulation>> |
| Document number | <<FILL: e.g. FDS-2026-02>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Modality | <<FILL: protein / oligonucleotide (naked or LNP) / viral vector (AAV)>> |
| Linked formulation development plan | <<FILL: document number>> |
| Protocol owner | <<FILL: e.g. Formulation Development Lead>> |
1. Purpose
This protocol defines the stress conditions, sampling schedule, and analytical readouts needed to demonstrate that the analytical methods supporting <<FILL: product>> can detect, resolve, and quantify degradation products, and to characterize the formulation’s own degradation pathways before those pathways are relied on to justify excipient selection or a presentation decision. A forced degradation study is not a stability study; it deliberately overstresses the product to a point normal storage and handling should never reach, then reads whether the method sees what happened.
2. Scope
| Dimension | Decision |
|---|---|
| Product / candidate formulation(s) in scope | <<FILL>> |
| Development stage | <<FILL: early screening / method validation support / formulation confirmation>> |
| Out of scope | <<FILL: e.g. real-time and accelerated stability, covered under a separate stability protocol; freeze-thaw cycling, covered under the paired freeze-thaw study protocol>> |
3. Responsibilities
| Role | Responsibility |
|---|---|
| Formulation scientist / lead | Selects stress conditions and target degradation extent appropriate to the modality’s dominant failure mode |
| Analytical development | Executes stress exposures, runs the analytical panel, confirms mass balance and method specificity |
| QA / Regulatory CMC | Confirms the study design supports the intended stability-indicating method validation claim |
4. Prerequisites
| Prerequisite | Evidence ref |
|---|---|
| Modality-specific dominant degradation mechanism identified (see the linked risk assessment) | <<FILL>> |
| Candidate analytical methods identified for each expected degradation pathway | <<FILL>> |
| Reference standard or well-characterized material available at sufficient quantity for stress exposure | <<FILL>> |
5. Stress conditions by mechanism
Select stress conditions from the rows relevant to this modality’s dominant degradation pathway, not the full list by default; a naked oligonucleotide formulation, for example, does not need an oxidative-stress arm sized for a protein’s methionine and tryptophan residues unless a specific chemistry-driven reason justifies one.
| Stress type | Typical condition | Applicable modality | What it is meant to reveal |
|---|---|---|---|
| Thermal | Elevated temperature, commonly a step series such as <<FILL: e.g. 40C, 50C, 60C>>, timed to reach the target degradation extent | Protein, oligonucleotide, viral vector | Thermally-driven aggregation, chemical degradation, or capsid instability, depending on modality |
| Photostability | Visible and UV light exposure per the option 1 confirmatory conditions in ICH’s photostability guidance | Protein, oligonucleotide; viral vector where light exposure during handling is a realistic risk | Photo-induced oxidation or other light-driven degradation pathways |
| Oxidative | Peroxide or, for some molecules, a radical initiator such as AAPH, at a defined concentration and exposure time | Protein (methionine, tryptophan oxidation) | Oxidative degradation pathways specific to susceptible residues |
| Acid / base hydrolysis | Defined pH extremes for a defined time, then neutralized before analysis | Protein, oligonucleotide (backbone hydrolysis, depurination) | pH-driven chemical degradation, the dominant oligonucleotide pathway |
| Mechanical / agitation | Defined shaking or stirring exposure, distinct from the freeze-thaw cycling covered under a separate protocol | Protein, viral vector (adsorption-driven aggregate formation) | Interfacial and mechanical-stress-driven aggregation or adsorption loss, independent of freeze-thaw |
| Metal-catalyzed oxidation | Defined trace-metal spike, e.g. iron or copper, at a defined concentration | Oligonucleotide, where a specific chemistry or modification pattern is known to be metal-sensitive | Metal-catalyzed oxidative pathways secondary to hydrolytic degradation |
Target degradation extent for each stress arm: enough degradation for the analytical method to resolve and quantify distinct degradation products, typically in the range of <<FILL: e.g. 5 to 20 percent loss of the parent species>>, without driving the sample to total degradation, which produces an uninterpretable mixture rather than resolvable peaks. State the target extent for each stress arm explicitly before execution; a study that runs “as long as convenient” instead of to a defined target extent cannot demonstrate the method was actually challenged.
6. Sampling and analytical panel
| Stress arm | Sampling timepoints | Analytical methods applied | Mass balance approach |
|---|---|---|---|
<<FILL>> | <<FILL: e.g. 0, intermediate, target extent>> | <<FILL: potency/purity method, size-variant method, charge-variant method, genome integrity assay for a viral vector>> | <<FILL: sum of parent and degradation product peak areas against the unstressed control, stated as a percentage>> |
State explicitly for every method applied whether it is expected to be stability-indicating for this stress arm, and confirm that expectation against the actual result, not just the method’s original validation scope for a different stress type.
7. Acceptance criteria
A stress arm succeeds when it reaches its target degradation extent, the analytical panel resolves at least one distinct, quantifiable degradation product not present in the unstressed control, and mass balance accounts for at least <<FILL: e.g. 95 percent>> of the starting material across parent and degradation products combined. A stress arm that reaches target extent but shows no resolvable new peak indicates either the wrong stress for this modality’s chemistry or an analytical method gap, and either explanation needs to be resolved before the method is relied on as stability-indicating.
8. Deviation handling
Any exposure that misses its target degradation extent, any analytical result inconsistent with the expected pathway for that stress type, or any departure from this protocol is recorded as a deviation per <<FILL: deviation SOP-ID>> at the point it is found, with an assessment of whether the deviation affects the study’s ability to support its intended conclusion.
9. Report commitments
The study lead issues a forced degradation summary report on completion: results by stress arm against the acceptance criteria in section 7, mass balance for each arm, a statement of which analytical methods are demonstrated stability-indicating for which degradation pathway, and the implication for the formulation’s dominant degradation mechanism as understood entering this study. This report feeds directly into the Formulation Development Report and into the analytical method’s own ICH Q2(R2)/Q14 validation package.
10. References
ICH Q1A(R2), Stability Testing of New Drug Substances and Products. ICH Q1B, Photostability Testing of New Drug Substances and Products. ICH Q2(R2), Validation of Analytical Procedures. ICH Q14, Analytical Procedure Development. ICH Q5C, Quality of Biotechnological Products: Stability Testing.
Confirm the current version of each reference before issue. A consolidated ICH Q1 guideline replacing the Q1A(R2) through Q1E and Q5C series, and explicitly extending stability-testing scope to advanced therapy medicinal products and other complex biologics for the first time, was in public draft as of this writing (FDA docket FDA-2025-D-1106); confirm whether it has reached Step 4 adoption before citing it as the applicable standard rather than the current guidelines above.
11. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
12. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Formulation lead) | <<FILL>> | ||
| Reviewer (Analytical Development) | <<FILL>> | ||
| Approver (QA) | <<FILL>> |
Filled specimen
Extract for Acme Therapeutics’ ATX-207, a naked antisense oligonucleotide candidate formulation, forced degradation study supporting stability-indicating method validation.
| Stress arm | Condition | Target extent | Result | Mass balance |
|---|---|---|---|---|
| Thermal | 60C for 96 hours | 10 to 15% parent loss | 12% parent loss; n-1 and n+2 length-variant species resolved by the ion-pair chromatography method | 98.4% |
| Acid hydrolysis | pH 2.0, 25C, 48 hours, then neutralized | 10 to 15% parent loss | 14% parent loss; backbone cleavage products consistent with acid-catalyzed hydrolysis, resolved and distinct from the n-1/n+2 thermal products | 97.1% |
| Base hydrolysis | pH 12.0, 25C, 24 hours, then neutralized | 10 to 15% parent loss | 18% parent loss, slightly above target; depurination-consistent products resolved | 96.0% |
| Photostability | ICH option 1 confirmatory exposure | Detect any light-driven pathway | No new degradation product distinguishable from thermal/hydrolytic products at the tested exposure; no oxidative stress arm run, molecule’s chemistry carries no photolabile group identified in the risk assessment | 99.1% (essentially unstressed) |
No oxidative or metal-catalyzed stress arm was run for this candidate; the linked formulation modality stress risk assessment identified hydrolytic backbone cleavage and length-variant growth, not oxidation, as the dominant pathway for this specific chemistry, and the protocol scoped the stress conditions accordingly rather than running a full generic panel.
Conclusion: the ion-pair chromatography method resolved distinct, quantifiable degradation products from three independent stress mechanisms, each with mass balance above the 95% acceptance threshold, supporting a stability-indicating claim for the method’s ICH Q2(R2) validation package. The photostability result, essentially unstressed, is reported as a negative finding consistent with the risk assessment’s prediction, not treated as a method failure.
Common inspection findings this protocol prevents
- A forced degradation study run to a round, convenient time point rather than a defined target degradation extent, so the analytical method was never actually challenged.
- A stress condition applied generically across every program regardless of modality, running an oxidative arm sized for protein chemistry against a naked oligonucleotide with no oxidation-susceptible pathway in scope.
- A stability-indicating claim asserted for an analytical method with no forced degradation data behind it, or with degradation data from a different formulation or a different stress type than the one actually claimed.
- Mass balance not calculated or not reported, so a reviewer cannot tell whether the degradation products account for the material lost from the parent peak.
How to adapt this protocol
- Start from the modality’s dominant degradation mechanism, identified in the linked risk assessment, and select only the stress arms in section 5 relevant to that mechanism; state explicitly which arms were deliberately excluded and why.
- Set a defined target degradation extent for every arm before execution, not an exposure time chosen for convenience.
- Confirm every analytical method applied is being evaluated against the specific degradation pathway it is expected to detect, and report mass balance for every arm.
- Feed the completed study directly into the analytical method’s ICH Q2(R2)/Q14 validation package and into the formulation development report.
- Confirm the current status of the consolidated ICH Q1 draft referenced in section 10 before citing it as settled guidance.